GSK (NYSE:GSK) Stock Acquired Rep. Bruce Westerman

by · The Cerbat Gem

Representative Bruce Westerman (R-Arkansas) recently bought shares of GSK plc (NYSE:GSK). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

  • Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
  • Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
  • Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
  • Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
  • Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
  • Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
  • Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
  • Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
  • Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
  • Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.

GSK Trading Up 1.5 %

Shares of GSK stock traded up $0.55 during mid-day trading on Friday, hitting $35.92. The stock had a trading volume of 4,812,738 shares, compared to its average volume of 4,642,413. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $74.10 billion, a P/E ratio of 22.59, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The firm has a 50-day moving average of $37.44 and a two-hundred day moving average of $36.14.

GSK (NYSE:GSK – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Shareholders of record on Friday, February 21st were paid a $0.3932 dividend. The ex-dividend date was Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.38%. GSK’s dividend payout ratio (DPR) is 100.63%.

Institutional Investors Weigh In On GSK

Institutional investors have recently bought and sold shares of the business. Indiana Trust & Investment Management Co increased its position in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust acquired a new position in shares of GSK in the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. increased its stake in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Sierra Ocean LLC acquired a new stake in GSK in the fourth quarter valued at $32,000. Finally, Parkside Financial Bank & Trust boosted its position in GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 818 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GSK shares. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday. They set a “neutral” rating and a $35.25 price objective on the stock. Eight research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $40.58.

View Our Latest Stock Report on GSK

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also